MARKER FOR DETERMINING SENSITIVITY OF IRINOTECAN-CONTAINING ANTI-CANCER AGENT THERAPY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 25, 2021
app pub date -
Mar 15, 2019
filing date -
Mar 29, 2018
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Provided is a novel marker for determining anti-cancer agent sensitivity. The present invention provides a marker for determining sensitivity to an anti-cancer agent, the anti-cancer agent including irinotecan or SN-38 or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof, the marker comprising one or more molecules selected from the group consisting of 5A4CR, ALA, ASP, CYS, CSSG, GLC3P, HIS, ILE, LEU, LYS, METSF, N6TLY, N6ALY, OCTA, SER, TUCA, THR, TRP, TYR and VAL. The present invention also provides a marker for determining sensitivity to an anti-cancer agent, the anti-cancer agent including irinotecan or SN-38 or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof, the marker comprising one or more molecules selected from the group consisting of 3IND, 4OVAL, 5A4CR, ALA, BENZA, CREAT, CSSG, DECNA, GABB, GLC3P, HYPTA, LYS, METSF, N8ASR, QUINA, SARCO, TMNO and VAL.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully